Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Plaque Psoriasis
Interventions: 122-0551 Foam, Vehicle Foam; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 21
States / cities: Fort Smith, Arkansas • Hot Springs, Arkansas • Encino, California + 18 more

Conditions: Scalp Psoriasis
Interventions: Roflumilast Foam 0.3%, Vehicle Foam; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 36
States / cities: Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 31 more

Conditions: Plaque Psoriasis
Interventions: roflumilast cream 0.3%, Zoryve, Placebo; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Psoriasis
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • Fountain Valley, California • Sacramento, California + 12 more

Conditions: Psoriatic Arthritis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 31
States / cities: Phoenix, Arizona • San Diego, California • Palm Harbor, Florida + 28 more

Conditions: Psoriasis, Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Tufts Medical Center; Other
Eligibility: 10 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Inflammatory Bowel Diseases
Interventions: Serial Biopsy; Procedure
Lead sponsor: Terrence A Barrett; Other
Eligibility: 18 Years to 90 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Nail Psoriasis
Interventions: Methotrexate, Triamcinolone Acetonide 10mg/mL, Saline; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis
Interventions: Taclonex Topical Suspension; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Psoriasis
Interventions: IDP-118 Lotion, HP Monad Lotion, Ultravate Cream, Tazorac Cream; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 12
States / cities: Anaheim, California • Encino, California • San Diego, California + 9 more

Conditions: Arthritis, Psoriatic
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 50
States / cities: Mountain Brook, Alabama • Avondale, Arizona • Flagstaff, Arizona + 46 more

Conditions: Plaque Psoriasis
Interventions: Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 20
States / cities: Beverly Hills, California • Northridge, California • San Diego, California + 16 more

Conditions: Psoriasis, Overweight or Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 38
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 34 more

Conditions: Healthy Volunteer, Psoriasis
Interventions: ABBV-547, ABBV-547 Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Bryant, Arkansas • Anaheim, California + 15 more

Conditions: Psoriatic Arthritis
Interventions: Guselkumab, Golimumab; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 14
States / cities: Loxahatchee Groves, Florida • Plant City, Florida • Riverview, Florida + 11 more

Conditions: Psoriasis
Interventions: transcutaneous electrical nerve stimulation (TENS) unit; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Psoriasis
Interventions: IDP-122 Vehicle Lotion, IDP-122 Vehicle Cream, IDP-122 Lotion, Ultravate Cream; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 13
States / cities: Rogers, Arkansas • Beverly Hills, California • Carlsbad, California + 10 more

Conditions: Palmo-plantar Psoriasis
Interventions: Apremilast, Placebo; Drug
Lead sponsor: Innovaderm Research Inc.; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Arlington Heights, Illinois

Conditions: Psoriasis, Inflammation
Interventions: Methotrexate, Ustekinumab, Etanercept, Adalimumab, Acitretin, UVB Excimer Laser, Narrowband UVB; Drug · Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Psoriasis Vulgaris
Interventions: CTLA4Ig / Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 1998
U.S. locations: 10
States / cities: San Diego, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Plaque Psoriasis
Interventions: CHS-1420, Adalimumab; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 28
States / cities: Phoenix, Arizona • Encino, California • Sacramento, California + 23 more

Conditions: Psoriasis
Interventions: erlotinib, placebo tablet; Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Dermatitis, Psoriasis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: San Diego, California • Denver, Colorado

Conditions: Plaque Psoriasis
Interventions: Bimekizumab; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: East Windsor, New Jersey • New York, New York

Search by objective public record fields.

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Peds Metabolic Syndrome in Psoriasis

Regulation of Mucosal Healing in Inflammatory Bowel Disease

Local Methotrexate Injections for the Treatment of Nail Psoriasis

A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

Use of Transcutaneous Electrical Nerve Stimulation for Reducing Biologic Injection Site Pain(TENS Study)

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

Apremilast in Palmo-Plantar Psoriasis

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis

Erlotinib for Treatment of Psoriasis

Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis

Bimekizumab in Plaque Psoriasis